Ma Kuang Healthcare Holding Limited (4139) AI Stock Analysis

Ma Kuang Healthcare Holding Limited

(TPEx:4139)

Select Model

Rating:42Neutral

Price Target:TWD 34.00▼(-4.49% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily weighed down by deteriorating profitability, a net loss, negative return on equity, and elevated leverage. Positive cash generation and some support from the price remaining above its 200-day moving average are insufficient to offset the weak financial and valuation profile.

Positive Factors

Resilient Cash GenerationStrong operating and free cash flow despite reported losses indicates that the clinic business can convert activity into cash and maintain internal funding capacity. This resilience provides a buffer for ongoing operations and debt service, although the recent decline in cash generation reduces its durability.

Negative Factors

Revenue and Profitability DeclineTwo consecutive years of revenue decline, combined with a swing from profit to a sizable net loss, signals weakening demand or operating performance rather than a temporary earnings fluctuation. Continued contraction would reduce scale benefits, constrain reinvestment, and make recovery in profitability more difficult.

Ma Kuang Healthcare Holding Limited (4139) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.56B
Dividend Yield: ―
Average Volume (3M): 38.45K
Price to Earnings (P/E): -15.1
Beta (1Y): -0.04
Revenue Growth: -0.75%
EPS Growth: -1491.75%
Country: TW
Employees: 466
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

Ma Kuang Healthcare Holding Limited Business Overview & Revenue Model

Company Description

Ma Kuang Healthcare Holding Limited, established in 2009 and headquartered in Kaohsiung, Taiwan, functions as an investment holding firm with a broad international and domestic presence in the healthcare sector. The company's core business involves a...

Ma Kuang Healthcare Holding Limited Financial Statement Overview

Summary

Weak overall financial performance. Profitability deteriorated sharply, with declining revenue and margins and a substantial net loss. Elevated leverage and negative return on equity remain concerns, while positive operating and free cash flow provide partial support.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.09B	1.09B	1.13B	1.22B	1.06B	959.45M
Gross Profit	120.68M	123.30M	150.47M	171.77M	160.70M	173.16M
EBITDA	114.62M	176.07M	271.13M	207.80M	182.48M	217.92M
Net Income	-106.56M	-67.08M	10.28M	-42.53M	-30.90M	38.54M
Balance Sheet
Total Assets	1.30B	1.38B	1.41B	1.57B	1.55B	1.35B
Cash, Cash Equivalents and Short-Term Investments	71.22M	126.19M	73.54M	91.72M	91.79M	85.24M
Total Debt	670.72M	686.85M	710.35M	881.32M	828.58M	651.11M
Total Liabilities	866.76M	904.75M	906.70M	1.10B	1.06B	816.62M
Stockholders Equity	410.54M	441.90M	458.64M	408.57M	430.22M	466.06M
Cash Flow
Free Cash Flow	150.06M	213.81M	313.48M	151.65M	43.97M	191.44M
Operating Cash Flow	174.23M	238.90M	340.13M	199.59M	189.88M	232.07M
Investing Cash Flow	-33.95M	-68.39M	-7.39M	-28.47M	-138.59M	-40.22M
Financing Cash Flow	-225.13M	-113.28M	-367.16M	-167.82M	-78.86M	-187.70M

Ma Kuang Healthcare Holding Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4139 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4111	76Outperform	TWD 1.71B	9.16	―	4.56%	5.33%	13.75%
TW:4911	72Outperform	TWD 1.74B	18.66	―	4.66%	-26.73%	-34.96%
TW:1294	67Neutral	TWD 1.62B	11.43	―	6.70%	20.43%	4.47%
TW:1295	59Neutral	TWD 1.58B	10.17	―	7.14%	-5.28%	-27.33%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4139	42Neutral	TWD 1.59B	-15.09	―	―	-0.75%	-1491.75%
TW:4127	40Underperform	TWD 1.65B	23.91	―	―	52.12%	―

* General Sector Average

Performance Comparison

TW:4139 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4139	Ma Kuang Healthcare Holding Limited	35.60	11.65	48.64%
TW:1294	Hantech Bio-Technology Co., Ltd.	44.80	-14.06	-23.88%
TW:1295	Synbio Tech Inc	41.90	-49.75	-54.28%
TW:4111	Chi Sheng Pharma & Biotech Co., Ltd.	28.50	-0.20	-0.71%
TW:4127	Tien Liang Biotech Co., Ltd.	36.15	5.15	16.61%
TW:4911	G&E Herbal Biotechnology Co., Ltd.	25.00	-18.42	-42.42%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Ma Kuang Healthcare Holding Limited AI Stock Analysis